Journal
MOVEMENT DISORDERS
Volume 24, Issue 3, Pages 425-428Publisher
WILEY
DOI: 10.1002/mds.22375
Keywords
myoclonus; dystonia; Epsilon-Sarcoglycan; Levodopa
Categories
Funding
- National Institute of Neurological Disorders and Stroke [K23NS047256]
- Thomas J. Hartman Foundation for Parkinson's Research
Ask authors/readers for more resources
Myoclonus-dystonia (M-D) is characterized by early-onset myoclonus and dystonia, and is often due to mutations in the epsilon-sarcoglycan gene (SCGE) at locus 7q21. The pathogenesis of M-D is poorly understood, and in a murine knockout model, dopaminergic hyperactivity has been postulated as a mechanism. We present two unrelated individuals with M-D due to SCGE deletions who displayed a robust and sustained response to levodopa (L-dopa) treatment. In contrast to using dopamine blocking agents suggested by the hyperdopaminergic knockout model, we propose that a trial of L-dopa may be considered in patients with myoclonus-dystoma. (C) 2009 Movement Disorder Society
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available